edited_Bakris.qxp 13/7/09 05:13 Page 64
Albuminuria
1. Carroll MF, Temte JL, Proteinuria in adults: a diagnostic 2009;19(1):61–2. 41. Chrysostomou A, Becker G, Spironolactone in addition to
approach, Am Fam Physician, 2000;62(6):1333–40. 23. Heeg JE, de Jong PE, van der Hem GK, et al., Efficacy and ACE inhibition to reduce proteinuria in patients with
2. K/DOQI clinical practice guidelines on hypertension and variability of the antiproteinuric effect of ACE inhibition by chronic renal disease, N Engl J Med, 2001;345(12):925–6.
antihypertensive agents in chronic kidney disease, Am J lisinopril, Kidney Int, 1989;36(2):272–9. 42. Epstein M, Williams GH, Weinberger M, et al., Selective
Kidney Dis, 2004;43(5 Suppl. 1):S1–290. 24. Vogt L, Waanders F, Boomsma F, et al., Effects of dietary aldosterone blockade with eplerenone reduces
3. Mancia G, De BG, Dominiczak A, et al, 2007 Guidelines for sodium and hydrochlorothiazide on the antiproteinuric albuminuria in patients with type 2 diabetes, Clin J Am Soc
the Management of Arterial Hypertension: the Task Force efficacy of losartan, J Am Soc Nephrol, 2008;19(5):999–1007. Nephrol, 2006;1(5):940–51.
for the Management of Arterial Hypertension of the 25. Chobanian AV, Bakris GL, Black HR, et al., Seventh Report 43. Rahman M, Brown CD, Coresh J, et al., The prevalence of
European Society of Hypertension (ESH) and of the of the Joint National Committee on Prevention, Detection, reduced glomerular filtration rate in older hypertensive
European Society of Cardiology (ESC), J Hypertens, Evaluation, and Treatment of High Blood Pressure, patients and its association with cardiovascular disease: a
2007;25(6):1105–87. Hypertension, 2003;42(6):1206–52. report from the Antihypertensive and Lipid-Lowering
4. American Diabetes Association, Nephropathy in diabetes, 26. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, The effect of Treatment to Prevent Heart Attack Trial, Arch Intern Med,
Diabetes Care, 2008;27:S79–S84. angiotensin-converting-enzyme inhibition on diabetic 2004;164(9):969–76.
5. Bakris GL, Microalbuminuria, Marker of kidney and nephropathy.The Collaborative Study Group, N Engl J Med, 44. Bakris GL, Copley JB, Vicknair N, et al., Calcium channel
cardiovascular disease, London: Current Medicine Group, 1993;329(20):1456–62. blockers versus other antihypertensive therapies on
2007. 27. Randomised placebo-controlled trial of effect of ramipril progression of NIDDM associated nephropathy, Kidney Int,
6. Duka I, Bakris G, Influence of microalbuminuria in achieving on decline in glomerular filtration rate and risk of terminal 1996;50(5):1641–50.
blood pressure goals, Curr Opin Nephrol Hypertens, renal failure in proteinuric, non-diabetic nephropathy. The 45. Bakris GL, Mangrum A, Copley JB, et al., Effect of calcium
2008;17(5):457–63. GISEN Group (Gruppo Italiano di Studi Epidemiologici in channel or beta-blockade on the progression of diabetic
7. Coresh J, Byrd-Holt D, Astor BC, et al., Chronic kidney Nefrologia), Lancet, 1997;349(9069):1857–63. nephropathy in African Americans, Hypertension,
disease awareness, prevalence, and trends among 28. Hou FF, Zhang X, Zhang GH, et al., Efficacy and safety of 1997;29(3):744–50.
U.S.adults, 1999 to 2000, J Am Soc Nephrol, benazepril for advanced chronic renal insufficiency, N Engl J 46. Bakris GL, Weir MR, Shanifar S, et al., Effects of blood
2005;16(1):180–88. Med, 2006;354(2):131–40. pressure level on progression of diabetic nephropathy:
8. Atkins RC, Polkinghorne KR, Briganti EM, et al., Prevalence 29. Major cardiovascular events in hypertensive patients results from the RENAAL study, Arch Intern Med,
of albuminuria in Australia: the AusDiab Kidney Study, randomized to doxazosin vs chlorthalidone: the 2003;163(13):1555–65.
Kidney Int Suppl, 2004;(92):S22–S24. Antihypertensive and Lipid-Lowering Treatment to Prevent 47. Smith AC, Toto R, Bakris GL, Differential effects of calcium
9. Cirillo M, Senigalliesi L, Laurenzi M, et al., Microalbuminuria Heart Attack Trial (ALLHAT), ALLHAT Collaborative Research channel blockers on size selectivity of proteinuria in
in nondiabetic adults: relation of blood pressure, body Group, JAMA, 2000;283(15):1967–75. diabetic glomerulopathy, Kidney Int, 1998;54(3):889–96.
mass index, plasma cholesterol levels, and smoking: the 30. Casas JP, Chua W, Loukogeorgakis S, et al., Effect of 48. Griffin KA, Hacioglu R, Abu-Amarah I, et al., Effects of
Gubbio Population Study. Arch Intern Med, inhibitors of the renin-angiotensin system and other calcium channel blockers on “dynamic” and “steady-state
1998;158(17):1933–9. antihypertensive drugs on renal outcomes: systematic step” renal autoregulation, Am J Physiol Renal Physiol,
10. Peterson JC, Adler S, Burkart JM, et al., Blood pressure review and meta-analysis, Lancet, 2005;366(9502):2026–33. 2004;286(6):F1136–F1143.
control, proteinuria, and the progression of renal disease. 31. Brenner BM, Cooper ME, de ZD, et al., Effects of losartan 49. Efficacy of atenolol and captopril in reducing risk of
The Modification of Diet in Renal Disease Study, Ann Intern on renal and cardiovascular outcomes in patients with macrovascular and microvascular complications in type 2
Med, 1995;123(10):754–62. type 2 diabetes and nephropathy, N Engl J Med, diabetes: UKPDS 39, UK Prospective Diabetes Study Group,
11. Jafar TH, Stark PC, Schmid CH, et al., Proteinuria as a 2001;345(12):861–9. BMJ, 1998;317(7160):713–20.
modifiable risk factor for the progression of non-diabetic 32. Lewis EJ, Hunsicker LG, Clarke WR, et al., Renoprotective 50. Kalaitzidis R, Bakris G, Should nephrologists use beta-
renal disease, Kidney Int, 2001;60(3):1131–40. effect of the angiotensin-receptor antagonist irbesartan in blockers? A perspective, Nephrol Dial Transplant,
12. Burton C, Harris KP, The role of proteinuria in the patients with nephropathy due to type 2 diabetes, N Engl J 2009;24(3):701–2.
progression of chronic renal failure, Am J Kidney Dis, Med, 2001;345(12):851–60. 51. Bakris GL, Fonseca V, Katholi RE, et al., Differential effects
1996;27(6):765–75. 33. Eijkelkamp WB, Zhang Z, Remuzzi G, et al., Albuminuria is a of beta-blockers on albuminuria in patients with type 2
13. Sarafidis PA, Riehle J, Bogojevic Z, et al., A comparative target for renoprotective therapy independent from blood diabetes, Hypertension, 2005;46(6):1309–15.
evaluation of various methods for microalbuminuria pressure in patients with type 2 diabetic nephropathy: post 52. Rachmani R, Levi Z, Slavachevsky I, et al., Effect of an
screening, Am J Nephrol, 2008;28(2):324–9. hoc analysis from the Reduction of Endpoints in NIDDM alpha-adrenergic blocker, and ACE inhibitor and
14. Khosla N, Sarafidis PA, Bakris GL, Microalbuminuria, Clin Lab with the Angiotensin II Antagonist Losartan (RENAAL) trial, J hydrochlorothiazide on blood pressure and on renal
Med, 2006;26(3):635–vii. Am Soc Nephrol, 2007;18(5):1540–46. function in type 2 diabetic patients with hypertension and
15. Tight blood pressure control and risk of macrovascular and 34. Barnett AH, Bain SC, Bouter P, et al., Angiotensin-receptor albuminuria. A randomized cross-over study, Nephron,
microvascular complications in type 2 diabetes: UKPDS 38. blockade versus converting-enzyme inhibition in type 2 1998;80(2):175–82.
UK Prospective Diabetes Study Group, BMJ, 1998;317(7160): diabetes and nephropathy, N Engl J Med, 2004;351(19): 53. Cooper KL, McKiernan JM, Kaplan SA, Alpha-adrenoceptor
703–13. 1952–61. antagonists in the treatment of benign prostatic
16. Hansson L, Zanchetti A, Carruthers SG, et al., Effects of 35. Yusuf S, Teo KK, Pogue J, et al., Telmisartan, ramipril, or hyperplasia, Drugs, 1999;57(1):9–17.
intensive blood-pressure lowering and low-dose aspirin in both in patients at high risk for vascular events, N Engl J 54. Kunz R, Friedrich C, Wolbers M, Mann JF, Meta-analysis:
patients with hypertension: principal results of the Med, 2008;358(15):1547–59. effect of monotherapy and combination therapy with
Hypertension Optimal Treatment (HOT) randomised trial. 36. Mann JF, Schmieder RE, McQueen M, et al., Renal inhibitors of the renin angiotensin system on proteinuria in
HOT Study Group, Lancet, 1998;351(9118):1755–62. outcomes with telmisartan, ramipril, or both, in people at renal disease, Ann Intern Med, 2008;148(1):30–48.
17. Sarnak MJ, Greene T, Wang X, et al., The effect of a lower high vascular risk (the ONTARGET study): a multicentre, 55. Parving HH, Persson F, Lewis JB, et al., Aliskiren combined
target blood pressure on the progression of kidney randomised, double-blind, controlled trial, Lancet, with losartan in type 2 diabetes and nephropathy, N Engl J
disease: long-term follow-up of the modification of diet in 2008;372(9638):547–53. Med, 2008;358(23):2433–46.
renal disease study, Ann Intern Med, 2005;142(5):342–51. 37. Messerli FH, The sudden demise of dual renin-angiotensin 56. Bidani A, Controversy about COOPERATE ABPM trial data,
18. Wright Jr JT, Bakris G, Greene T, et al., Effect of blood system blockade or the soft science of the surrogate end Am J Nephrol, 2006;26(6):629–32.
pressure lowering and antihypertensive drug class on point, J Am Coll Cardiol, 2009;53(6):468–70. 57. Hollenberg NK, Aldosterone in the development and
progression of hypertensive kidney disease: results from 38. Weber MA, Bakris GL, Dahlof B, et al., Baseline progression of renal injury, Kidney Int, 2004;66(1):1–9.
the AASK trial, JAMA, 2002;288(19):2421–31. characteristics in the Avoiding Cardiovascular events 58. Pitt B, Reichek N, Willenbrock R, et al., Effects of
19. Gaede P, Vedel P, Larsen N, et al., Multifactorial intervention through Combination therapy in Patients Living with eplerenone, enalapril, and eplerenone/enalapril in patients
and cardiovascular disease in patients with type 2 Systolic Hypertension (ACCOMPLISH) trial: a hypertensive with essential hypertension and left ventricular
diabetes, N Engl J Med, 2003;348(5):383–93. population at high cardiovascular risk, Blood Press, hypertrophy: the 4E-left ventricular hypertrophy study,
20. Bakris GL, Slowing nephropathy progression: focus on 2007;16(1):13–19. Circulation, 2003;108(15):1831–8.
proteinuria reduction, Clin J Am Soc Nephrol, 2008;3(Suppl. 1): 39. Brater DC, Diuretic therapy, N Engl J Med, 59. Bakris GL, Weir MR, DeQuattro V, McMahon FG, Effects of
S3–10. 1998;339(6):387–95. an ACE inhibitor/calcium antagonist combination on
21. Mailloux LU, Haley WE, Hypertension in the ESRD patient: 40. Rossing K, Schjoedt KJ, Smidt UM, et al., Beneficial effects proteinuria in diabetic nephropathy, Kidney Int,
pathophysiology, therapy, outcomes, and future directions, of adding spironolactone to recommended 1998;54(4):1283–9.
Am J Kidney Dis, 1998;32(5):705–19. antihypertensive treatment in diabetic nephropathy: a 60. Bakris GL, Sowers JR, ASH position paper: treatment of
22. Ritz E, Koleganova N, Piecha G, Role of sodium intake in randomized, double-masked, cross-over study, Diabetes hypertension in patients with diabetes-an update, J Clin
the progression of chronic kidney disease, J Ren Nutr, Care, 2005;28(9):2106–12. Hypertens (Greenwich), 2008;10(9):707–5.
64 US NEPHROLOGY
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92